Imine reductase mutant and application thereof in synthesis of optically pure 2-aryl pyrrolidine

Through the amino acid sequence mutation and recombinant expression technology of imine reductase SvIRED, its catalytic activity and stability are improved, the problems of low activity and substrate inhibition in the prior art are solved, and the efficient 2-arylpyrroline is achieved Asymmetric hydrogenation reduction provides a green and efficient synthesis pathway for chiral 2-arylpyrrolidine.

CN118909993APending Publication Date: 2024-11-08EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411129249.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing imine reductase SvIRED has low activity and severe substrate inhibition, resulting in low asymmetric hydrogenation reduction efficiency of 2-arylpyrroline, and the inability to efficiently synthesize chiral 2-arylpyrrolidin intermediates.

Method used

SvIRED is subjected to specific mutations in the amino acid sequence through protein engineering technology, which improves its catalytic vitality and stability, forms mutants such as SvIREDM3, and achieves efficient asymmetric hydrogenation of 2-arylpyrroline through the construction of recombinant expression vectors and transformants. reduction.

Benefits of technology

It significantly improves the catalytic activity and substrate tolerance of imine reductase, and can efficiently catalyze the asymmetric hydrogenation of 2-(3,5-dimethylphenyl)pyrroline, the optical purity of the product is greater than 99%, and the substrate concentration is Up to 100g/L, it overcomes the phenomenon of substrate inhibition and is suitable for green enzymatic synthesis of drugs such as atecalon.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004997351190000011
    Figure BDA0004997351190000011
  • Figure BDA0004997351190000021
    Figure BDA0004997351190000021
  • Figure BDA0004997351190000081
    Figure BDA0004997351190000081
Patent Text Reader

Abstract

The invention belongs to the technical field of bioengineering, and relates to an imine reductase mutant and application thereof in synthesis of optically pure 2-aryl pyrrolidine. The specific activity of the imine reductase mutant for catalyzing the 2-(3, 5-dimethylphenyl) pyrroline is up to 136.8 U / mg, and the imine reductase mutant can efficiently catalyze the asymmetric reduction of the 2-(3, 5-dimethylphenyl) pyrroline to synthesize the chiral intermediate (S)-2-(3, 5-dimethylphenyl) pyrrolidine of atekiren (Aticaprant). In the enzymatic reaction coupled with resin in-situ adsorption, the substrate concentration is as high as 100g / L, the space time yield of the product is as high as 438g / L / d, and the optical purity is greater than 99%. In addition, the imine reductase mutant also has relatively high specific activity, conversion rate and optical activity for other various 2-aryl pyrrolines. In conclusion, the imine reductase mutant provided by the invention has extremely high catalytic activity and space time yield, the problem of substrate inhibition is effectively solved, and the imine reductase mutant has a relatively strong industrial application prospect in synthesis of chiral 2-aryl pyrrolidine, especially an atecaram chiral intermediate (S)-2-(3, 5-dimethylphenyl) pyrrolidine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of bioengineering technology, and relates to an imine reductase mutant and its application in the synthesis of optically pure 2-arylpyrrolidines. Specifically, it relates to an imine reductase SvIRED mutant derived from the bacterium Streptomyces viridochromogene and its encoding nucleic acid, a recombinant expression vector and a recombinant expression transformant containing the imine reductase mutant nucleic acid, a catalyst containing the recombinant imine reductase mutant, and its application in catalyzing the asymmetric reduction of 2-arylpyrroline to prepare chiral 2-arylpyrrolidines. Background Art

[0002] Chiral amines are important chiral auxiliary agents and key synthetic intermediates for medicines and natural products. Currently, about 40% of chiral drug molecules contain chiral amine structural units. Cyclic chiral amines have both the characteristics of amines and the special activity of heterocyclic compounds. As important intermediates, they are widely used in the synthesis of natural products and chiral drugs (C&EN, 2018, 96, 26-30). Among them, chiral 2-substituted pyrrolidines are the skeleton structures of many natural products and bioactive molecules, especially 2-aryl substituted pyrrolidine derivatives. For example, a highly selective neurotrophin receptor kinase inhibitor drug larotrectinib was approved by the FDA in 2018 for the treatment of tumors, as well as several antagonists for the treatment of depression (J. Med. Chem. 2011, 54, 8000–8012).

[0003]

[0004] The opioid receptor (OR) system includes mu (MOR), delta (DOR), kappa (KOR), and opioid receptors (ORL-1). KOR is widely expressed in the central nervous system, spinal cord, and peripheral tissues. The use of KOR agonists in human trials is limited because they exhibit anxiety, irritability, and depression. A large amount of animal model evidence confirms that aversion, anxiety, and depressive behaviors are associated with KOR agonists, while KOR antagonists can alleviate these behaviors (Psychopharmacology 2020, 237, 3715–3728). Aticaprant is a short-acting, high-affinity, selective KOR antagonist (Neuropsychopharmacology 2018, 43, 1805–1812), and its structure is as follows:

[0005]

[0006] Regarding the synthesis of chiral 2-substituted pyrrolidines, Helmchen used rhodium catalysts to carry out asymmetric hydrogenation of allylamine in 2009 to synthesize various chiral 2-substituted pyrrolidines (C. Synlett, 2009, 4, 1413-1416). Zhang used Ir-f-Binaphane catalysts to reduce a series of 2-aryl pyrrolines to generate various chiral 2-aryl pyrrolidines (Adv. Synth. Catal., 2010, 352, 3121-3125). However, these chemical processes not only use heavy metal catalysts such as iridium, rhodium and ruthenium, but also require complex protection and deprotection processes. Therefore, it is urgent to develop a more green, efficient and safe synthesis method.

[0007] Enzymatic asymmetric reduction has many advantages such as high selectivity, mild reaction conditions, and simple operation. Therefore, the enzymatic asymmetric reduction of imines to synthesize chiral amines has attracted more and more attention in recent years. Imine reductase (IRED) is a class of NADPH-dependent oxidoreductases that can catalyze the asymmetric reduction of potential chiral cyclic imines to synthesize chiral amines with high enantioselectivity (ChemCatChem, 2015, 7, 579-583). At the same time, imine reductase can catalyze the reductive amination reaction of carbonyl groups. This enzyme is a subclass of imine reductase, called reductive aminase (RedAm), which can catalyze the asymmetric reductive amination reaction of ketones or aldehydes with amines in solution (Nat.Chem., 2017, 9, 961-969).

[0008] In 2010, two strains of Streptomyces were found to be able to catalyze the cyclic imine 2-methylpyrroline to produce (R)- or (S)-2-methylpyrrolidine. The researchers isolated the enzymes and then conducted reverse genetics studies. Through gene sequencing and heterologous expression, they finally identified two imine reductases, SIR and RIR, which can catalyze the synthesis of a series of cyclic amines (ChemCatChem, 2013, 5, 3505-3508). The identification of the sequence promoted the research boom of imine reductase, and the sequence information provided by the research group also laid the foundation for the subsequent gene mining of imine reductase.

[0009] In previous studies, the inventors cloned an imine reductase SvIRED from the bacterium Streptomyces viridochromogene. The enzyme can catalyze the asymmetric hydrogenation reduction of various 2-aryl pyrrolines with high stereoselectivity to synthesize chiral 2-aryl pyrrolidines, including catalyzing the asymmetric hydrogenation reduction of 2-(3,5-dimethylphenyl) pyrroline to prepare the chiral intermediate (S)-2-(3,5-dimethylphenyl) pyrrolidine of Aticaprant (Org. Lett., 2017, 19, 3151-3154). However, the enzyme has the problems of low activity and severe substrate inhibition. The specific activity for 2-(3,5-dimethylphenyl) pyrroline is only 1.6 U / mg, and it can only convert 1g / L of substrate. Summary of the invention

[0010] The purpose of the present invention is to overcome the problems and shortcomings of low activity and severe substrate inhibition of imine reductase SvIRED in the prior art, molecularly transform the wild-type imine reductase SvIRED through protein engineering technology, obtain an imine reductase mutant with significantly improved activity, stability and substrate tolerance, and realize its application in the synthesis of optically pure 2-arylpyrrolidine, and provide a green pathway for the asymmetric hydrogenation reduction of 2-arylpyrrolidine to synthesize chiral 2-arylpyrrolidine, including a green enzymatic pathway for the synthesis of articaprant chiral intermediate (S)-2-(3,5-dimethylphenyl)pyrrolidine and its analogs.

[0011] This application selects 2-(3,5-dimethylphenyl)pyrroline as a model substrate, and transforms the catalytic performance of SvIRED by means of protein engineering, significantly improving the catalytic activity of the enzyme and reducing the substrate inhibition effect, thereby achieving an efficient and green enzymatic synthesis of (S)-2-(3,5-dimethylphenyl)pyrrolidine, and also providing a green and efficient enzymatic synthesis process for chiral 2-arylpyrrolidines, which will accelerate the application of imine reductase in industry.

[0012] The purpose of the present invention can be achieved by the following technical solutions:

[0013] One of the technical solutions adopted by the present invention is to provide an imine reductase mutant, wherein the imine reductase parent is SvIRED (the DNA sequence of the parent is shown in SEQ ID No. 1; the encoded protein is imine reductase, and its amino acid sequence is shown in SEQ ID No. 2) from Streptomyces viridochromogene; mutating the imine reductase SvIRED to obtain a protein encoding a new amino acid sequence formed by replacing one or more of the amino acid residues at position 214, methionine at position 221, tyrosine at position 137, valine at position 130, aspartic acid at position 131, isoleucine at position 135, alanine at position 217, leucine at position 97, threonine at position 40, threonine at position 73, isoleucine at position 127 and alanine at position 126 with other amino acid residues, which is the imine reductase mutant; specifically, the imine reductase mutant is a mutant obtained by causing any of the following mutations in the amino acid sequence of the wild-type imine reductase SvIRED:

[0014] (1) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, and the result was named SvIRED M214L ;

[0015] (2) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, and the tyrosine at position 221 was replaced with arginine, and the residue was named SvIRED. M1 ;

[0016] (3) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, the tyrosine at position 221 was replaced with arginine, and the valine at position 137 was replaced with isoleucine, and the resulting product was named SvIRED M1-1 ;

[0017] (4) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, the tyrosine at position 221 was replaced with arginine, the valine at position 137 was replaced with isoleucine, and the aspartic acid at position 130 was replaced with tryptophan, and the resulting protein was named SvIRED. M1-2 ;

[0018] (5) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, the tyrosine at position 221 was replaced with arginine, the valine at position 137 was replaced with isoleucine, the aspartic acid at position 130 was replaced with tryptophan, and the isoleucine at position 131 was replaced with leucine, and the residue was named SvIRED. M1-3 ;

[0019] (6) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 was replaced by leucine, the tyrosine at position 221 was replaced by arginine, the valine at position 137 was replaced by isoleucine, the aspartic acid at position 130 was replaced by tryptophan, the isoleucine at position 131 was replaced by leucine, and the alanine at position 135 was replaced by arginine, and the resulting protein was named SvIRED. M1-4 ;

[0020] (7) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, isoleucine at position 137, tryptophan at position 130, isoleucine at position 131, leucine at position 135, alanine at position 135, and arginine at position 217, and is named SvIRED. M1-5 ;

[0021] (8) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, valine at position 137, isoleucine at position 130, tryptophan at position 131, leucine at position 135, arginine at position 136, valine at position 217, and leucine at position 97, and named SvIRED. M2 ;

[0022] (9) The amino acid sequence of SEQ ID No. 2 in the sequence listing is substituted with leucine at position 214, tyrosine at position 221 with arginine, valine at position 137 with isoleucine, aspartic acid at position 130 with tryptophan, isoleucine at position 131 with leucine, alanine at position 135 with arginine, valine at position 217 with leucine, leucine at position 97 with tyrosine, and threonine at position 40 with arginine, and is named SvIRED. M2-1 ;

[0023] (10) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, valine at position 137, isoleucine at position 130, tryptophan at position 131, leucine at position 135, arginine at position 136, valine at position 217, leucine at position 97, tyrosine at position 98, threonine at position 40, and serine at position 73, and is named SvIRED. M2-2 ;

[0024] (11) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, valine at position 137, isoleucine at position 130, tryptophan at position 131, leucine at position 135, arginine at position 136, valine at position 217, leucine at position 97, tyrosine at position 98, arginine at position 109, threonine at position 110, serine at position 127, and isoleucine at position 127. The residue is named SvIRED. M2-3 ;

[0025] (12) In the amino acid sequence shown in SEQ ID No. 2 in the sequence listing, methionine at position 214 is replaced by leucine, tyrosine at position 221 is replaced by arginine, valine at position 137 is replaced by isoleucine, aspartic acid at position 130 is replaced by tryptophan, isoleucine at position 131 is replaced by leucine, alanine at position 135 is replaced by arginine, valine at position 217 is replaced by leucine, leucine at position 97 is replaced by tyrosine, threonine at position 40 is replaced by arginine, threonine at position 73 is replaced by serine, isoleucine at position 127 is replaced by proline, and alanine at position 126 is replaced by glycine, and the resulting protein is named SvIRED. M3 .

[0026] Furthermore, the method for obtaining the mutant is specifically as follows:

[0027] The gene sequence of the wild-type imine reductase SvIRED from Streptomyces viridochromogene was used as a template, site-directed saturation mutagenesis was used to construct a mutant library, and each round of constructed mutant library was subjected to high-throughput screening to obtain the above-mentioned various mutants. The high-throughput screening refers to: random mutation or single-point saturation mutation of the imine reductase SvIRED, activity detection using the substrate 2-(3,5-dimethylphenyl)pyrroline, and screening for mutants with significantly improved activity.

[0028] The whole plasmid PCR amplification for constructing the site-directed saturation mutation library is a conventional technique in the art. The PCR amplification reaction system is: 1 ng template, 0.5 μL (10 μM) of each pair of mutation primers, 12.5 μL PrimeSTAR HS (Premix), and sterile distilled water to 25 μL.

[0029] The PCR amplification procedure is as follows: (1) denaturation at 98°C for 3 min; (2) denaturation at 98°C for 10 s, (3) annealing at 60°C for 10 s, and (4) extension at 72°C for 7 min. Steps (2) to (4) are repeated 20 times, and finally, extension is performed at 72°C for 7 min. The product is stored at 12°C.

[0030] The second technical solution adopted by the present invention is to provide an isolated nucleic acid, wherein the nucleic acid encodes the imine reductase mutant described in the first technical solution.

[0031] Furthermore, the preparation method of the nucleic acid is a conventional preparation method in the art, and the preparation method comprises: obtaining a nucleic acid molecule encoding the imine reductase mutant by gene cloning technology, or obtaining a nucleic acid molecule encoding the imine reductase mutant by an artificial full sequence synthesis method; preferably, using the mutant DNA sequence obtained in technical solution 1 as a template, PCR amplification is performed on the desired target gene to obtain the nucleic acid molecule with a point mutation.

[0032] The PCR amplification technique is a conventional technique in the art. The system of the PCR amplification reaction is: 1 ng template, 0.5 μL (10 μM) of upstream and downstream mutation primers, 12.5 μL PrimeSTAR HS (Premix), and sterile distilled water to 25 μL. The PCR amplification procedure is: (1) denaturation at 98°C for 3 min; (2) denaturation at 98°C for 10 s, (3) annealing at 60°C for 10 s, (4) extension at 72°C for 7 min, steps (2) to (4) are performed for 20 cycles in total, and finally extension is performed at 72°C for 7 min, and the PCR product is stored at 12°C.

[0033] The third technical solution adopted by the present invention is to provide a recombinant expression vector containing the above-mentioned nucleic acid.

[0034] Furthermore, the recombinant expression vector can be obtained by conventional methods in the art, that is, the nucleic acid molecule of the imine reductase mutant gene of the present invention is connected to various commercially available expression vectors to construct; the expression vector is preferably plasmid pET-28a(+). Taking plasmid pET-28a(+) as an example, the recombinant expression plasmid of the present invention can be obtained by the following method: the nucleic acid product obtained by PCR amplification and the expression vector pET-28a(+) are double-digested with restriction endonucleases Nco I and Xho I, respectively, to form complementary sticky ends, and then connected with T4 DNA ligase to form a recombinant expression plasmid containing the imine reductase gene of the present invention.

[0035] The fourth technical solution adopted by the present invention is to provide a recombinant expression transformant comprising the above-mentioned recombinant expression vector.

[0036] The method for preparing the recombinant expression transformant is preferably: transforming the above-mentioned recombinant expression vector into a host microorganism; the host microorganism is preferably Escherichia coli (abbreviated as E. coli), more preferably Escherichia coli BL21 (DE3). The aforementioned recombinant expression vector is transformed into Escherichia coli BL21 (DE3) to obtain the preferred genetically engineered strain of the present invention. The plasmid transformation method can be selected from conventional methods in the art, such as electroporation, heat shock, etc., preferably heat shock; the operation steps of the heat shock method are: mixing the recombinant plasmid solution with the competent cells, heat shock at 42°C for 90s, then ice bathing for 2min, then resuming at 37°C for 35min, coating LB agar medium plates containing 50μg / mL kanamycin, and culturing to obtain the target recombinant expression transformant.

[0037] The fifth technical solution adopted by the present invention is to provide an imine reductase mutant catalyst, which can be in any of the following forms:

[0038] (1) culturing the recombinant expression transformant of the present invention, and isolating transformant cells containing the imine reductase mutant, i.e., resting cells of the recombinant expression transformant;

[0039] (2) culturing the recombinant expression transformant of the present invention, isolating and crushing the transformant cells containing the imine reductase mutant to obtain a crude enzyme solution, or purifying and separating the crude enzyme solution to obtain a pure enzyme solution;

[0040] (3) Cultivating the recombinant expression transformant of the present invention, isolating and crushing the transformant cells containing the imine reductase mutant to obtain a crude enzyme solution, and freeze-drying the crude enzyme solution to obtain a crude enzyme powder.

[0041] The preparation method of the recombinant imine reductase mutant catalyst is preferably as follows: the recombinant Escherichia coli is inoculated into LB medium (yeast extract 5 g / L, peptone 10 g / L, NaCl 10 g / L) containing kanamycin (50 μg / mL), shake-cultured at 37°C overnight, inoculated into a shake flask containing 100 mL TB medium (yeast extract 24 g / L, peptone 12 g / L, KH2PO4 2.31 g / L, K2HPO4 12.54 g / L, glycerol 5 g / L) at an inoculum volume of 1% (v / v), placed in a shaker at 37°C and 200 rpm for shaking culture, and when the absorbance OD 600When the pH reaches 0.6 to 0.8, add isopropyl-β-D-thiogalactoside (IPTG) with a final concentration of 0.2mM for induction, and the induction temperature is 16°C. After 24 hours of induction, the culture medium is centrifuged and washed twice with physiological saline to obtain resting cells; the resting cells obtained are suspended in KPB buffer (100mM, pH 6.0), ultrasonically broken in an ice water bath, and the supernatant is collected by centrifugation, which is the crude enzyme solution of the recombinant enzyme. The crude enzyme solution is analyzed by polyacrylamide gel electrophoresis, and the recombinant protein exists in the cell in a completely soluble form; the crude enzyme solution is subjected to separation and purification operations to obtain a pure enzyme solution; the crude enzyme solution is freeze-dried to obtain freeze-dried crude enzyme powder.

[0042] The purification operation is an operation that is easily understood and implemented by those skilled in the art, and is preferably a Ni column affinity chromatography method; the freeze-drying refers to precooling the crude enzyme solution and then placing it in a freeze dryer for freeze drying for about 30 to 80 hours to obtain a freeze-dried enzyme powder.

[0043] The sixth technical solution adopted by the present invention is to provide the use of the imine reductase mutant or the imine reductase mutant catalyst in catalyzing the asymmetric reduction reaction of 2-arylpyrroline to form 2-arylpyrrolidine; the 2-arylpyrroline is selected from any one of the structures shown in S1-S24:

[0044]

[0045] In the application of the imine reductase mutant or the imine reductase mutant catalyst in catalyzing the asymmetric reduction reaction of 2-arylpyrroline to form 2-arylpyrrolidine, 2-arylpyrroline is used as a substrate, and in the presence of the coenzyme NADPH, the imine reductase mutant or the imine reductase mutant catalyst is used to catalyze the asymmetric reduction of 2-arylpyrroline to prepare 2-arylpyrrolidine, and NADPH is oxidized to generate NADP + During the reaction, the glucose dehydrogenation reaction catalyzed by glucose dehydrogenase is coupled to convert NADP + Enzymatic reduction regenerates it to NADPH.

[0046] Further, the conditions of the asymmetric reduction reaction can be selected according to the conventional conditions of such reactions in the art. The application conditions are preferably: the reaction is carried out in an aqueous phase, the concentration of the substrate 2-arylpyrroline is 2 to 50 g / L, the concentration of the cosolvent DMSO is 5% (v / v), the pure enzyme of the imine reductase mutant is 0.1 mg, and the coenzyme NADP is additionally added. + The concentration is 1mM, the concentration of co-substrate glucose is 20-700mM, the amount of glucose dehydrogenase added is 0.1-30kU / L, the reaction pH is 6.0, and the reaction temperature is 30°C.

[0047] Furthermore, when the application is used to prepare optically pure (S)-2-(3,5-dimethylphenyl)pyrrolidine using 2-(3,5-dimethylphenyl)pyrroline (S1) as a substrate, the generated optically pure (S)-2-(3,5-dimethylphenyl)pyrrolidine can be used as a chiral intermediate for synthesizing Aticaprant.

[0048] Compared with the prior art, the present invention has the following advantages and effects:

[0049] (1) The imine reductase mutant of the present invention has higher catalytic activity and thermal stability. The catalytic activity of the imine reductase mutant for the 2-(3,5-dimethylphenyl)pyrroline substrate is as high as 136.8 U / mg, which is much higher than that of the currently reported imine reductase. The mutant can efficiently catalyze the asymmetric reduction of 2-(3,5-dimethylphenyl)pyrroline to synthesize the chiral intermediate (S)-2-(3,5-dimethylphenyl)pyrrolidine of Aticaprant. The substrate concentration in the enzymatic reaction is as high as 100 g / L, which effectively overcomes the serious substrate inhibition phenomenon of the existing imine reductase. The product space-time yield is as high as 438 g / L / d, and the optical purity is greater than 99%. The substrate concentration and space-time yield are much higher than those of the currently reported imine reductase-catalyzed process.

[0050] (2) The imine reductase mutant SvIRED provided by the present invention M3 When catalyzing the asymmetric reduction of 2-arylpyrroline, the optical activity is good, the optical purity of the product is greater than 98%, and the conversion rate is all above 88%.

[0051] (3) Compared with metal catalysis, the enzyme catalyst catalytic reaction described in the present invention has the advantages of high product optical purity, mild reaction conditions, safe operation, green and environmentally friendly process, etc., and has a good prospect for industrial application. DETAILED DESCRIPTION

[0052] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is described in detail below in conjunction with specific embodiments. It should be noted that the following embodiments will help those skilled in the art to further understand the present invention, but do not limit the present invention in any form. It should be noted that for those of ordinary skill in the art, several variations and improvements can also be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.

[0053] In the examples, the recombinant plasmid pET28a(+)-SvIRED was constructed by the inventors themselves; the cation exchange resin D152 was purchased from Shanghai Huazhen Technology Co., Ltd.

[0054] Unless otherwise stated, the specific experiments in the following examples were performed according to conventional methods and conditions in the art, or in accordance with the commercial instructions of the kits.

[0055] Example 1 Site-directed mutagenesis and initial screening of imine reductase SvIRED

[0056] The PCR amplification technique was used to introduce base mutations into the imine reductase SvIRED gene sequence (the gene sequence of SvIRED is shown in SEQ ID No. 1), wherein the upstream and downstream primer sequences used are shown in SEQ ID No. 3 and SEQ ID No. 4, wherein N represents a mixture of four bases A, T, C, and G; K represents a mixture of two bases G and T; and M represents a mixture of two bases A and C. The template used was the recombinant plasmid pET28a(+)-SvIRED of the imine reductase SvIRED.

[0057] The above PCR amplification products were transformed into E. coli BL21 (DE3) competent cells and evenly spread on LB agar plates containing 50 μg / mL kanamycin, and cultured at 37°C overnight to construct a random mutant library. Single clones were selected and cultured in deep-well plates. Each well of the primary plate contained 300 μL LB medium (containing 50 μg / mL kanamycin), and cultured at 37°C and 800 rpm overnight. 20 μL of the primary seed solution was transferred to each well of the secondary plate containing 600 μL LB medium (containing 50 μg / mL kanamycin), and cultured at 37°C and 800 rpm for 3 hours until the OD 600 When the p-value was about 1.0, IPTG was added to a final concentration of 0.2 mM for induction, and the culture was continued at 16°C for 24 h. The cells were centrifuged at 3500 rpm for 10 min, and the supernatant was discarded. 200 μL of lysis solution (containing 350 mg / L lysozyme and 12 mg / L DNA enzyme) was added to each well. The cells were fully suspended by shaking, lysed at 37°C for 2 h, and centrifuged at 3500 rpm for 10 min. 10 μL of supernatant was respectively aspirated to a 96-well ELISA plate, and 190 μL of KPB buffer (100 mM, pH 6.0) containing 1-15 mM 2-(3,5-methylphenyl)pyrroline and 0.15 mM NADPH was added. The absorbance change at 340 nm was detected by an ELISA instrument to perform preliminary activity screening of the mutant library, and mutants with improved activity to the substrate 2-(3,5-methylphenyl)pyrroline were screened for sequence determination. The imine reductase mutant obtained by screening is a mutant obtained by causing any of the following mutations in the amino acid sequence of the wild-type imine reductase SvIRED:

[0058] (1) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, and the result was named SvIRED M214L ;

[0059] (2) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, and the tyrosine at position 221 was replaced with arginine, and the residue was named SvIRED. M1 ;

[0060] (3) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, the tyrosine at position 221 was replaced with arginine, and the valine at position 137 was replaced with isoleucine, and the resulting product was named SvIRED M1-1 ;

[0061] (4) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, the tyrosine at position 221 was replaced with arginine, the valine at position 137 was replaced with isoleucine, and the aspartic acid at position 130 was replaced with tryptophan, and the resulting protein was named SvIRED. M1-2 ;

[0062] (5) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence list was replaced with leucine, the tyrosine at position 221 was replaced with arginine, the valine at position 137 was replaced with isoleucine, the aspartic acid at position 130 was replaced with tryptophan, and the isoleucine at position 131 was replaced with leucine, and the residue was named SvIRED. M1-3 ;

[0063] (6) The methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 was replaced by leucine, the tyrosine at position 221 was replaced by arginine, the valine at position 137 was replaced by isoleucine, the aspartic acid at position 130 was replaced by tryptophan, the isoleucine at position 131 was replaced by leucine, and the alanine at position 135 was replaced by arginine, and the resulting protein was named SvIRED. M1-4 ;

[0064] (7) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, isoleucine at position 137, tryptophan at position 130, isoleucine at position 131, leucine at position 135, alanine at position 135, and arginine at position 217, and is named SvIRED. M1-5 ;

[0065] (8) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, valine at position 137, isoleucine at position 130, tryptophan at position 131, leucine at position 135, arginine at position 136, valine at position 217, and leucine at position 97, and named SvIRED. M2 ;

[0066] (9) The amino acid sequence of SEQ ID No. 2 in the sequence listing is substituted with leucine at position 214, tyrosine at position 221 with arginine, valine at position 137 with isoleucine, aspartic acid at position 130 with tryptophan, isoleucine at position 131 with leucine, alanine at position 135 with arginine, valine at position 217 with leucine, leucine at position 97 with tyrosine, and threonine at position 40 with arginine, and is named SvIRED. M2-1 ;

[0067] (10) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, valine at position 137, isoleucine at position 130, tryptophan at position 131, leucine at position 135, arginine at position 136, valine at position 217, leucine at position 97, tyrosine at position 98, threonine at position 40, and serine at position 73, and is named SvIRED. M2-2 ;

[0068] (11) The amino acid sequence of SEQ ID No. 2 in the sequence listing is replaced by leucine at position 214, arginine at position 221, valine at position 137, isoleucine at position 130, tryptophan at position 131, leucine at position 135, arginine at position 136, valine at position 217, leucine at position 97, tyrosine at position 98, arginine at position 109, threonine at position 110, serine at position 127, and isoleucine at position 127. The residue is named SvIRED. M2-3 ;

[0069] (12) In the amino acid sequence shown in SEQ ID No. 2 in the sequence listing, methionine at position 214 is replaced by leucine, tyrosine at position 221 is replaced by arginine, valine at position 137 is replaced by isoleucine, aspartic acid at position 130 is replaced by tryptophan, isoleucine at position 131 is replaced by leucine, alanine at position 135 is replaced by arginine, valine at position 217 is replaced by leucine, leucine at position 97 is replaced by tyrosine, threonine at position 40 is replaced by arginine, threonine at position 73 is replaced by serine, isoleucine at position 127 is replaced by proline, and alanine at position 126 is replaced by glycine, and the resulting protein is named SvIRED. M3 .

[0070] Example 2 Expression, purification, enzyme activity and kinetics of imine reductase SvIRED mutant

[0071] The imine reductase mutant obtained in Example 1 was expressed, purified and assayed for activity. The specific steps are as follows:

[0072] Pick the recombinant expression single colony of the imine reductase mutant growing on the plate and inoculate it into a 4mL LB tube (containing kanamycin 50ng / μL), put it in a 37℃ shaker at 200rpm and culture it for 10-12h, then transfer the bacterial liquid to 100mL LB medium (containing kanamycin 50ng / μL) at an inoculation ratio of 1:50, put it in a 37℃ shaker at 200rpm and culture it for 3h, and wait until its OD 600 When the p-value reaches 0.6-0.8, add 20 μL IPTG (1M) to induce the expression of the target protein. After culturing at 16°C and 200 rpm for 24 hours, collect the bacteria by centrifugation. Suspend the obtained resting cells in KPB buffer (100 mM, pH 6.0), ultrasonically disrupt in an ice water bath, and collect the supernatant by centrifugation to obtain the cell disruption solution of the recombinant imine reductase mutant. Freeze-dry the cell disruption solution to obtain the crude enzyme powder.

[0073] The imine reductase mutant protein was purified by Ni column affinity chromatography, and the specific method was as follows:

[0074] (1) Equilibrate the affinity Ni column (bed volume 5 mL) with sodium phosphate buffer (20 mM, pH 7.5, containing 500 mM NaCl);

[0075] (2) Resuspend 1 g of the resting cells obtained above in 10 mL of sodium phosphate buffer (20 mM, pH 7.5, containing 500 mM NaCl), disrupt by ultrasound (the power of the cell disruptor is 15% for 15 min), centrifuge at 12,000 rpm for 45 min, collect the supernatant, and pass it through a Ni column at a flow rate of 1 mL / min to allow the target protein to bind to the Ni column;

[0076] (3) Elute the impure proteins with 10 mL of sodium phosphate buffer (20 mM, pH 7.5, containing 500 mM NaCl) containing 0-50 mM imidazole;

[0077] (4) Elute the target protein with 10 mL of sodium phosphate buffer (20 mM, pH 7.5, containing 500 mM NaCl) containing 250 mM imidazole;

[0078] (5) The collected protein samples were subjected to SDS-PAGE electrophoresis. 20 μL of sample was added to 5 μL 5×SDS loading buffer and heated at 90°C for 20 min. The electrophoresis loading volume was 10 μL. The standard molecular weight protein (Protein Molecular Weight Marker) was purchased from Thermo Company, USA. The concentration of SDS-PAGE gel was 12%, and 90 V voltage was used for concentration and 120 V voltage was used for separation.

[0079] 50 mM 2-(3,5-dimethylphenyl)pyrroline, 10 mM NADPH and KPB buffer (100 mM, pH 6.0) were added to 1 mL of the system, and the activity of the recombinant imine reductase mutant was determined by detecting the change in absorbance at 340 nm. The results are shown in Table 1.

[0080] The activity of the recombinant imine reductase mutant was determined by adding 0.1-200 mM 2-(3,5-dimethylphenyl)pyrroline, 10 mM NADPH and KPB buffer (100 mM, pH 6.0) to 1 mL of the system and detecting the change in absorbance at 340 nm. The kinetic parameters (K i , K m and k cat ) According to the activity and substrate concentration at different substrate concentrations, according to the formula V max *[S] / (K m +[S]+[S]^2 / K i ) is fitted, and the results are shown in Table 1.

[0081] Table 1 Kinetic parameter characterization of SvIRED and its mutants

[0082]

[0083] The results in the above table show that all the imine reductase mutants obtained in Example 1 have been improved in specific activity to varying degrees, which preliminarily indicates that the mutations introduced in this application have beneficial effects on specific activity; in particular, the mutant SvIRED M3The specific activity of the mutant SvIRED was as high as 136.8 U / mg, which was 85.5 times that of the parent SvIRED. M3 The catalytic activity was significantly improved; in addition, the mutant SvIRED M2 and SvIRED M1 The specific activities of the mutants were 8.0 U / mg and 3.5 U / mg, which were 5 and 2.19 times that of the parent SvIRED, respectively, indicating that the catalytic activities of the two mutants were also slightly improved. M3 K cat / K m The mutant SvIRED has an affinity for the substrate of 819.42, which is 15.8 times higher than that of the parent SvIRED. This indicates that the mutant has an improved affinity for the substrate. This is also a strong evidence that the mutant overcomes the severe substrate inhibition of the wild-type imine reductase. Therefore, the mutant SvIRED was selected in this application. M3 For subsequent experiments.

[0084] Example 3 Imine reductase SvIRED and its mutant SvIRED M3 Activity towards various 2-arylpyrrolines

[0085] 20 mM 2-arylpyrroline S1-S24, 10 mM NADPH and KPB buffer (100 mM, pH 6.0) were added to 1 mL of the system, and the absorbance change at 340 nm was detected to measure the activity of SvIRED and its mutant SvIRED. M3 The activity was measured and the results are shown in Table 2.

[0086] Table 2 SvIRED and its mutants SvIRED M3 Activity towards various 2-arylpyrrolines

[0087]

[0088] In the table, +++ indicates the mutant SvIRED M3 Compared with the parent SvIRED, the activity is increased by more than 80 times or the activity is increased from zero to one; ++ indicates mutant SvIRED M3 Compared with the parent SvIRED, the specific activity is increased by 20 to 80 times; + indicates mutant SvIRED M3 Compared with the parent SvIRED, the specific activity is increased by 1 to 20 times; - indicates mutant SvIRED M3 Compared with the parent strain SvIRED, the specific activity is lower.

[0089] The results in the table above show that the mutant SvIRED M3The activity of substrates S1-S5, S7, S10-S16, and S19 were all improved to varying degrees, among which the activity of S1 was significantly improved, and the activity of S19 was increased from zero to something. This may be because the catalytic pocket is more suitable for substrate binding, making the hydrogen donation distance of the cofactor closer.

[0090] Example 4 Imine reductase SvIRED and its mutant SvIRED M3 Catalyzes the asymmetric reduction of various 2-arylpyrrolines

[0091] Add KPB buffer (100 mM, pH 6.0), 100 mM substrate, 150 mM glucose, and 1 mM NADP to a 500 μL reaction system. + , 1.5mg BmGDH freeze-dried enzyme powder and 0.5mg SvIRED or SvIRED M3 Pure enzyme, place the Ep tube at 30℃, 1000rpm for 24h. After the reaction, add 20μL NaOH (10M) solution to adjust the pH to above 13 to terminate the reaction. Add an equal volume of methyl tert-butyl ether to the reaction solution for extraction, take the upper organic phase, add an appropriate amount of anhydrous sodium sulfate and dry for 8h, detect the substrate reaction by gas chromatography, detect the ee value by GC or HPLC, and judge the absolute configuration of the product by circular dichroism. The chiral analysis method is shown in Table 3, and the results are shown in Table 4.

[0092] Table 3 Analysis method of product amines

[0093]

[0094]

[0095] The specific operations of acetylation and butyrylation described in the table are:

[0096] Product acetylation: Take 0.3 mL of methyl tert-butyl ether extract, place it in a 2 mL Ep tube, add 100 μL of acetic anhydride and 10 μL of pyridine, place it in a reactor at 40°C for 4 hours, wash it three times with 500 μL of saturated brine after completion, take the upper organic phase and evaporate the solvent at room temperature.

[0097] Butyrylation of the product: Take 0.3 mL of methyl tert-butyl ether extract, place it in a 2 mL Ep tube, add 100 μL of butyric anhydride and 10 μL of pyridine, place it in a reactor at 40°C for 4 hours, wash it three times with 500 μL of saturated brine after completion, take the upper organic phase and dilute it with an appropriate amount of methyl tert-butyl ether for gas chromatography analysis.

[0098] Trifluoroacetylation of the product: Take 0.3 mL of methyl tert-butyl ether extract, place it in a 2 mL Eppendorf tube, add 100 μL of trifluoroacetic anhydride and 10 μL of pyridine, place it in a reactor at 40°C for 4 hours, wash it three times with 500 μL of saturated brine after completion, take the upper organic phase and dilute it with an appropriate amount of methyl tert-butyl ether for gas chromatography analysis.

[0099] Table 4 SvIRED and SvIRED M3 Catalytic transformation of 2-arylarylpyrrolines

[0100]

[0101]

[0102]

[0103] The results in the table show that the conversion rates of the parent SvIRED to these 2-arylpyrroline substrates are mostly less than 60%, while the imine reductase mutant SvIRED provided by the present invention M3 The conversion rates of these 2-arylpyrrolidine substrates have been greatly improved, all above 88%; based on the original relatively good optical activity of the parent SvIRED, the mutants can maintain or improve the excellent optical activity, and the optical purity of the obtained product 2-arylpyrrolidine is greater than 98%.

[0104] Example 5 Enzymatic Scale Synthesis of Artikaren Chiral Intermediate (S)-2-(3,5-Dimethylphenyl)pyrrolidine

[0105] In a 250 mL jacketed reactor, 10 g of substrate 2-(3,5-dimethylphenyl)pyrroline (578 mM), 15.6 g of glucose (866 mM), and 78.8 mg of NADP were added. + (1mM), 2g SvIRED M3 Wet cells, 1g BmGDH freeze-dried enzyme powder and 15g D152 cation exchange resin (used for in-situ adsorption of products and substrates to reduce the inhibitory effect during the reaction), supplemented with KPB (100mM, pH6.0) buffer to 100mL, reacted at 30°C, 550rpm for 5h, the conversion rate reached 99%, then 10mL NaOH solution (10M) was added to quench the reaction, and an equal volume of methyl tert-butyl ether was added to extract three times and the organic phase was separated. The organic phases after three extractions were combined, added with an appropriate amount of anhydrous MgSO4 and dried overnight, and the solvent was removed by rotary evaporation to obtain 9.13g of product (S)-2-(3,5-dimethylphenyl)pyrrolidine, with an isolation yield of 90% and an optical purity greater than 99%.

[0106] The NMR spectrum results of the enzymatically synthesized product (S)-2-(3,5-dimethylphenyl)pyrrolidine are as follows: 1 H NMR (CDCl3, 400MHz): δppm=7.00(s,2H),6.89(s,1H),4.05(t,J=7.8Hz,1H),3.25–3.19(m,1 H),3.04–2.98(m,1H),2.33(s,6H),2.22–2.10(m,2H),1.98–1.83(m,2H),1.72–1.63(m,1H). 13 C NMR (CDCl3, 101MHz): δppm=144.7,137.8,128.4,124.3,62.6,47.0,34.3,25.6,21.3.

[0107] The sequence information involved in the present invention is as follows:

[0108] SEQ ID No.1 (nucleotide sequence of imine reductase SvIRED):

[0109] ATGGGATCGAACACCAACGCAGCCCAAGCTCCGGTGTCGGTCATCGGCCTGG

[0110] GCCTGATGGGCCAGGCATTAGCCGCTGCTTTCCTCAAGGCGGGGCACCCCAC

[0111] CACCGTATGGAACCGCACGGCCGCCAAGGCCGATCAGCTCGTCTCCGAGGGC

[0112] GCCACCCGCGCCGGTTCGGTCGCGGACGCGATCGCGGCGAGCCCGCTGGTC

[0113] GTCCTCTGCGTCACGGACTACGGCGCCGTGCGCGAGCTGCTCGACCCGCTGG

[0114] CCGGCTCGCTCAAGGGCAAGGTCGTGGTGAACCTGACCACGGGCACCTCGA

[0115] CGCAGGCCCGCGAGACCGCCGAGTGGGCGGCGGGCGTGGAGACCACCTACC

[0116] TCGACGGCGCCATCATGGCGATCCCGCCGGACATCGCCACCGACGCCGCCGT

[0117] CCTGCTGTACAGCGGCCCGAAGGCCGCCTTCGAGGAACACGAGGCGACGCT

[0118] GCGCGCGCTGGGCGCCGCGGGCACCACCTACCTGGACACCGACCACGGACT

[0119] GTCCGCGCTCTACGACATGTCGCTGCTGGGCATCATGTGGGGTGTCCTCAACG

[0120] GCTTCCTCCAGGGCGCCGCCCTGCTGGGCACCGCCAAGGTGAAGGCCACCA

[0121] CCTTCGCCCCGCTGGCCAACACGATGATCAACGTGATCACCGAGTATGTGAC

[0122] CGCGTACGCCCCGCAGATCGACGAGGGCAAGTACCCGGCCGGCGACGCCAC

[0123] CATGACGGTCCACCAGGACGCGATGGAGCACCTCGCCGAGGAGAGCGAGAC

[0124] CCTCGGCATCAGCGCCGAAATGCCCCGTTTCTTCAAGGCGCTCGCCGACCGC

[0125] GCGGTGGCCGACGGCCACGCCGACAGCGGCTACGCGGCAATGATCGAGCAG

[0126] TTCCGCAAGCCCTCCGCCTGA

[0127] SEQ ID No.2 (Amino acid sequence of imine reductase SvIRED):

[0128] MSNTNAAQAPVSVIGLGLMGQALAAAFLKAGHPTTVWNRTAAKADQLVSEGA

[0129] TRAGSVADAIAASPLVVLCVTDYGAVRELLDPLAGSLKGKVVVNLTTGTSTQAR

[0130] ETAEWAAGVETTYLDGAIMAIPPDIATDAAVLLYSGPKAAFEEHEATLRALGAA

[0131] GTTYLDTDHGLSALYDMSLLGIMWGVLNGFLQGAALLGTAKVKATTFAPLANT

[0132] MINVITEYVTAYAPQIDEGKYPAGDATMTVHQDAMEHLAEESETLGISAEMPRF

[0133] FKALADRAVADGHADSGYAAMIEQFRKPSA

[0134] SEQ ID No.3 (upstream primer sequence):

[0135] 5'-CGCCATCATGGCGNNKCCGCCGGACATCGCCACCG-3'

[0136] SEQ ID No.4 (downstream primer sequence):

[0137] 5'-CGGTGGCGATGTCCGGCGGMNNCGCCATGATGGCG-3'

[0138] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. An imine reductase mutant, characterized in that: The mutant is a protein having imine reductase activity corresponding to a new amino acid sequence formed by replacing one or more of the amino acid residues at position 214, the methionine at position 221, the tyrosine at position 137, the valine at position 130, the aspartic acid at position 131, the isoleucine at position 135, the alanine at position 135, the valine at position 217, the leucine at position 97, the threonine at position 40, the threonine at position 73, the isoleucine at position 127 and the alanine at position 126 in the amino acid sequence shown in SEQ ID No. 2 with other amino acid residues.

2. The imine reductase mutant according to claim 1, characterized in that: The imine reductase mutant has any one of the following sequences: (1) replacing the methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence listing with leucine; (2) the methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence listing is replaced with leucine, and the tyrosine at position 221 is replaced with arginine; (3) the methionine at position 214 of the amino acid sequence shown in SEQ ID No. 2 in the sequence listing is replaced with leucine, the tyrosine at position 221 is replaced with arginine, and the valine at position 137 is replaced with isoleucine; (4) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, and the aspartic acid at position 130 is replaced by tryptophan; (5) the methionine at position 214 of the amino acid sequence as shown in SEQ ID No. 2 in the sequence listing is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, and the isoleucine at position 131 is replaced by leucine; (6) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, and the alanine at position 135 is replaced by arginine; (7) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, the alanine at position 135 is replaced by arginine, and the valine at position 217 is replaced by leucine; (8) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, the alanine at position 135 is replaced by arginine, the valine at position 217 is replaced by leucine, and the leucine at position 97 is replaced by tyrosine; (9) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, the alanine at position 135 is replaced by arginine, the valine at position 217 is replaced by leucine, the leucine at position 97 is replaced by tyrosine, and the threonine at position 40 is replaced by arginine; (10) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, the alanine at position 135 is replaced by arginine, the valine at position 217 is replaced by leucine, the leucine at position 97 is replaced by tyrosine, the threonine at position 40 is replaced by arginine, and the threonine at position 73 is replaced by serine; (11) in the amino acid sequence of SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, the alanine at position 135 is replaced by arginine, the valine at position 217 is replaced by leucine, the leucine at position 97 is replaced by tyrosine, the threonine at position 40 is replaced by arginine, the threonine at position 73 is replaced by serine, and the isoleucine at position 127 is replaced by proline; (12) In the amino acid sequence shown in SEQ ID No. 2 in the sequence listing, the methionine at position 214 is replaced by leucine, the tyrosine at position 221 is replaced by arginine, the valine at position 137 is replaced by isoleucine, the aspartic acid at position 130 is replaced by tryptophan, the isoleucine at position 131 is replaced by leucine, the alanine at position 135 is replaced by arginine, the valine at position 217 is replaced by leucine, the leucine at position 97 is replaced by tyrosine, the threonine at position 40 is replaced by arginine, the threonine at position 73 is replaced by serine, the isoleucine at position 127 is replaced by proline, and the alanine at position 126 is replaced by glycine.

3. An isolated nucleic acid, characterized in that The nucleic acid encodes the imine reductase mutant according to claim 1 or 2.

4. A recombinant expression vector, characterized in that: Comprising the nucleic acid as claimed in claim 3.

5. A recombinant expression transformant, characterized in that: Comprising the recombinant expression vector as claimed in claim 4.

6. An imine reductase mutant catalyst, characterized in that: Is any of the following forms: (1) culturing the recombinant expression transformant according to claim 5, and isolating transformant cells containing the imine reductase mutant according to claim 1 or 2, i.e., resting cells of the recombinant expression transformant; (2) culturing the recombinant expression transformant according to claim 5, isolating and disrupting the transformant cells containing the imine reductase mutant according to claim 1 or 2 to obtain a crude enzyme solution, or purifying and separating the crude enzyme solution to obtain a pure enzyme solution; (3) Cultivating the recombinant expression transformant according to claim 5, isolating and disrupting the transformant cells containing the imine reductase mutant according to claim 1 or 2 to obtain a crude enzyme solution, and freeze-drying the crude enzyme solution to obtain a crude enzyme powder.

7. Use of the imine reductase mutant according to claim 1 or 2 or the imine reductase mutant catalyst according to claim 6, characterized in that: The application refers to the application in catalyzing the asymmetric reduction of 2-aryl pyrroline to synthesize chiral 2-aryl pyrrolidine.

8. The use according to claim 7, characterized in that Using 2-arylpyrroline as a substrate, in the presence of coenzyme NADPH, using the imine reductase mutant according to claim 1 or 2 or the imine reductase mutant catalyst according to claim 6, catalyzing the bioasymmetric reduction of 2-arylpyrroline to prepare chiral 2-arylpyrrolidine, and simultaneously oxidizing NADPH to generate NADP + .

9. The use according to claim 7, characterized in that The 2-aryl pyrroline is one of the following compounds: When the substrate is 2-(3,5-dimethylphenyl)pyrroline as shown in S1, the product is the chiral intermediate (S)-2-(3,5-dimethylphenyl)pyrrolidine for synthesizing artikalan.

10. The use according to claim 8, characterized in that Coupled with glucose dehydrogenase-catalyzed glucose dehydrogenation reaction, NADP + Enzymatic reduction regenerates it to NADPH.

Citation Information

Cited By

  • Imine reductase or mutant thereof, application of imine reductase or mutant thereof in synthesis of multi-ring-fused chiral nitrogen heterocyclic compound and method for synthesizing multi-ring-fused chiral nitrogen heterocyclic compound

    CN119220514A